Medication Prescribing

The FDA has expanded the indication of a proprotein convertase subtilisin/kexin type 9 inhibitor to include the reduction of risk for myocardial infarction, stroke, and unstable angina requiring...

The FDA has approved a second biosimilar to etanercept for the treatment of various autoimmune conditions.

The FDA has approved the first generic of naloxone hydrochloride nasal spray for the treatment of opioid overdose. The new option is intended for use by individuals without medical training.

The FDA has cleared for marketing the first medical device for the treatment of attention-deficit/hyperactivity disorder

The FDA has cleared for marketing the first medical device for the treatment of attention-deficit/hyperactivity disorder

The FDA has approved a new treatment option for adults with body mass index (BMI) of 25-40 kg/m2.

The FDA has approved a new option for the treatment of osteoporosis in postmenopausal women who have a high risk of fracture.

The FDA has approved a new option for the treatment of osteoporosis in postmenopausal women who have a high risk of fracture.

The FDA has approved a new option for the treatment of osteoporosis in postmenopausal women who have a high risk of fracture.

After 2 randomized clinical trials found it as safe and effective as the standard 3-drug regimen, the FDA approved the first 2-drug regimen for adults with HIV-1 who have never been treated with ART.